Show simple item record

dc.contributor.authorBatty, G.
dc.contributor.authorLi, Q.
dc.contributor.authorCzernichow, S.
dc.contributor.authorNeal, B.
dc.contributor.authorZoungas, S.
dc.contributor.authorHuxley, Rachel
dc.contributor.authorPatel, A.
dc.contributor.authorDe Galan, B.
dc.contributor.authorWoodward, M.
dc.contributor.authorHamet, P.
dc.contributor.authorHarrap, S.
dc.contributor.authorPoulter, N.
dc.contributor.authorChalmers, J.
dc.date.accessioned2017-01-30T11:39:20Z
dc.date.available2017-01-30T11:39:20Z
dc.date.created2016-09-12T08:36:30Z
dc.date.issued2010
dc.identifier.citationBatty, G. and Li, Q. and Czernichow, S. and Neal, B. and Zoungas, S. and Huxley, R. and Patel, A. et al. 2010. Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: Prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial. Journal of the American College of Cardiology. 56 (23): pp. 1908-1913.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/13762
dc.identifier.doi10.1016/j.jacc.2010.04.067
dc.description.abstract

Objectives The aim of this study was to examine the relationship between erectile problems in men and cardiovascular disease (CVD) mortality. Background Although there are plausible mechanisms linking erectile dysfunction (ED) with coronary heart disease (CHD) and stroke, studies are scarce. Methods In a cohort analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial population, 6,304 men age 55 to 88 years with type 2 diabetes participated in a baseline medical examination when inquiries were made about ED. Over 5 years of follow-up, during which study members attended repeat clinical examinations, the presence of fatal and nonfatal CVD outcomes, cognitive decline, and dementia was ascertained. Results After adjusting for a range of covariates, including existing illness, psychological health, and classic CVD risk factors, relative to those who were free of the condition, baseline ED was associated with an elevated risk of all CVD events (hazard ratio: 1.19; 95% confidence interval: 1.08 to 1.32), CHD (hazard ratio: 1.35; 95% confidence interval: 1.16 to 1.56), and cerebrovascular disease (hazard ratio: 1.36; 95% confidence interval: 1.11 to 1.67). Men who experienced ED at baseline and at 2-year follow-up had the highest risk for these outcomes. Conclusions In this cohort of men with type 2 diabetes, ED was associated with a range of CVD events. © 2010 American College of Cardiology Foundation.

dc.titleErectile dysfunction and later cardiovascular disease in men with type 2 diabetes: Prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial
dc.typeJournal Article
dcterms.source.volume56
dcterms.source.number23
dcterms.source.startPage1908
dcterms.source.endPage1913
dcterms.source.issn0735-1097
dcterms.source.titleJournal of the American College of Cardiology
curtin.departmentSchool of Public Health
curtin.accessStatusOpen access via publisher


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record